



HIV ENROLLMENT FORM

Fax To: 817-332-5363

PHARMACY LOCATION
Phone: 817-335-5712
Fax: 817-332-5363
800 8th Avenue, Suite 130
Fort Worth, TX 76104

DATE: _____ SHIP TO:
DATE NEEDED: _____ PATIENT OFFICE

PATIENT INFO
NAME _____ E-MAIL _____ DOB _____ MALE FEMALE
ADDRESS _____ CITY _____ STATE _____ ZIP _____
HOME TELEPHONE _____ MOBILE PHONE _____ SS# _____
Emergency Contact: _____ Emergency Contact Phone (____) - ____ - ____
Preferred Method of Contact Phone Email Height: _____ Weight _____ lbs. Allergies: _____
Current Medications: (attach additional pages if necessary) _____ Date _____

PRESCRIPTION BENEFITS INFORMATION (Please Attach front and back of insurance card)

Plan Name: _____ ID # _____ Group#: _____ RxBIN: _____ RxPCN: _____

Date of Diagnosis _____ CD4 Count _____ Date of Lab _____
Diagnosis (ICD-10 Code):
 B20 HIV Disease
 Z20.6 Contact with and (suspected) exposure to HIV
 Other: _____
HIV RNA _____ Date of Lab _____
Has patient been tested for:
 Hepatitis C? Y N If Yes, Positive Negative
 Hepatitis B? Y N If Yes, Positive Negative
New to Treatment? Y N **If No Prior HIV Treatment:**
Dates: _____ Drug Name _____
Reason for Discontinuation _____
Dates: _____ Drug Name _____
Reason for Discontinuation _____
Dates: _____ Drug Name _____
Reason for Discontinuation _____

MEDICATION		DOSE/STRENGTH	DIRECTIONS/SIG*	QTY	REFILLS	MEDICATION		DOSE/STRENGTH	DIRECTIONS/SIG*	QTY	REFILLS
COMBINATION ANTIRETROVIRALS						NRTIs					
<input type="checkbox"/> Biktarvy®	<input type="checkbox"/> 50/200/25 mg <input type="checkbox"/> 30/120/15 mg		Take 1 tablet QD			<input type="checkbox"/> Emtriva® (Emtricitabine)	200mg		Take 1 capsule QD		
<input type="checkbox"/> Cimduo®	300/300 mg		Take 1 tablet QD			<input type="checkbox"/> Emtriva® Oral solution	<input type="checkbox"/> 10mg/mL		Give _____ mg or _____ mL QD		
<input type="checkbox"/> Cabenuva Injectable Suspension	<input type="checkbox"/> 600/900 mg <input type="checkbox"/> 400/600 mg		<input type="checkbox"/>			<input type="checkbox"/> Epivir® (Lamivudine)	<input type="checkbox"/> 150mg <input type="checkbox"/> 300mg				
<input type="checkbox"/> Combivir® (Lamivudine/Zidovudine)	150/300 mg		Take 1 tablet BID			<input type="checkbox"/> Epivir® Oral Solution (Lamivudine)	<input type="checkbox"/> 10mg/mL		Give _____ mg or _____ mL QD		
<input type="checkbox"/> Complera™	200/25/300 mg		Take 1 tablet QD with food			<input type="checkbox"/> Retrovir® (Zidovudine)	10 mg/mL		Give _____ mg or _____ mL BID		
<input type="checkbox"/> Descovy®	<input type="checkbox"/> 200/25 mg <input type="checkbox"/> 120/15 mg		Take 1 tablet QD			<input type="checkbox"/> Viread® (Tenofovir Disoproxil Fumarate)	<input type="checkbox"/> 150mg <input type="checkbox"/> 200mg <input type="checkbox"/> 250mg <input type="checkbox"/> 300mg		Take _____ mg QD		
<input type="checkbox"/> Delstrigo™	100/300/300 mg		Take 1 tablet QD			<input type="checkbox"/> Ziagen® (Abacavir)	<input type="checkbox"/> 300mg				
<input type="checkbox"/> Dovato	50/300 mg		Take 1 tablet QD			<input type="checkbox"/> Zidovudine	<input type="checkbox"/> 100mg <input type="checkbox"/> 300mg		<input type="checkbox"/> Take 1 tablet QD <input type="checkbox"/> Take _____ capsule QD		
<input type="checkbox"/> Efavirenz/ Emtricitabine/Tenofovir	600/200/300mg		Take 1 tablet QD on an empty stomach			NNRTIs					
<input type="checkbox"/> Epcicom® (Abacavir/ Lamivudine)	600/300 mg		Take 1 tablet QD			<input type="checkbox"/> Edurant®	<input type="checkbox"/> 25mg		Take 1 tablet QD with food		
<input type="checkbox"/> Evotaz™	300/150 mg		Take 1 tablet QD with food			<input type="checkbox"/> Intelence® (Etravirine)	<input type="checkbox"/> 25mg <input type="checkbox"/> 100mg		Take _____ tablet(s) BID		
<input type="checkbox"/> Genvoia®	150/150/200/10 mg		Take 1 tablet QD with food			<input type="checkbox"/> Pifeltro™	100mg		Take 1 tablet QD with or without food		
<input type="checkbox"/> Juluca	50/25 mg		Take 1 tablet QD with food			<input type="checkbox"/> Sustiva® (Efavirenz)	<input type="checkbox"/> 50mg <input type="checkbox"/> 200mg <input type="checkbox"/> 600mg				
<input type="checkbox"/> Odefsey®	200/25/25 mg		Take 1 tablet QD with food			<input type="checkbox"/> Nevirapine	<input type="checkbox"/> 200mg <input type="checkbox"/> ER400mg <input type="checkbox"/> 50mg/5mL				
<input type="checkbox"/> Prezcoibix™	800/150 mg		Take 1 tablet QD with food			Pharmacokinetic Boosters					
<input type="checkbox"/> Stribild®	150/150/200/300 mg		Take 1 tablet QD with food			<input type="checkbox"/> Tybost®	150mg		Take 1 tablet QD		
<input type="checkbox"/> Symfi®	600/300/300 mg		Take 1 tablet HS on an empty stomach			PROTEASE INHIBITORS					
<input type="checkbox"/> Symfi Lo™	400/300/300 mg		Take 1 tablet HS on an empty stomach			<input type="checkbox"/> Aptivus®	250mg		Take 2 tablets BID		
<input type="checkbox"/> Tenofovir	600/200/300mg		Take 1 tablet QD on an empty stomach			<input type="checkbox"/> Kaletra® (Lopinavir – Ritonavir)	<input type="checkbox"/> 100mg/25mg <input type="checkbox"/> 200mg/50mg <input type="checkbox"/> 80-20mg/ML				
<input type="checkbox"/> Triumeq®	600/50/300 mg		Take 1 tablet QD			<input type="checkbox"/> Lexiva® (Fosamprenavir Calcium)	700 mg				
<input type="checkbox"/> Triumeq PD	60/50/30 mg		Disperse _____ tablets for oral suspension in 20ml of drinking water and give QD			<input type="checkbox"/> Norvir® (Ritonavir)	<input type="checkbox"/> 100mg Tablet <input type="checkbox"/> 100mg Powder				
<input type="checkbox"/> Trizivir	300/150/300 mg		Take 1 tablet BID			<input type="checkbox"/> Prezista®	<input type="checkbox"/> 75mg <input type="checkbox"/> 150mg <input type="checkbox"/> 600mg <input type="checkbox"/> 800mg <input type="checkbox"/> 100mg/mL				
<input type="checkbox"/> Truvada®	<input type="checkbox"/> 100/150 mg <input type="checkbox"/> 133/200 mg <input type="checkbox"/> 167/250 mg <input type="checkbox"/> 200/300 mg		<input type="checkbox"/> Take 1 tablet QD <input type="checkbox"/> Take 2 tablets 2 – 24 hours before intercourse, followed by 1 tablet 24 hours after the initial two-tablet dose, followed by 1 tablet 48 hours after the initial two-tablet dose			<input type="checkbox"/> Reyataz® (Atazanavir)	<input type="checkbox"/> 150mg <input type="checkbox"/> 200mg <input type="checkbox"/> 300mg				
INTEGRASE INHIBITORS						FUSION/ENTRY INHIBITORS					
<input type="checkbox"/> Isentress® Chewable	<input type="checkbox"/> 25mg <input type="checkbox"/> 100mg		Chew _____ tablets BID			<input type="checkbox"/> Fuzeon®	90mg vial				
<input type="checkbox"/> Isentress®	400mg		Take 1 tablet BID			<input type="checkbox"/> Selzentry® (Maraviroc)	<input type="checkbox"/> 150mg <input type="checkbox"/> 300mg <input type="checkbox"/> 20mg/mL				
<input type="checkbox"/> Isentress® HD	600mg		Take 2 tablets QD			OTHER					
<input type="checkbox"/> Tivicay®	<input type="checkbox"/> 10mg <input type="checkbox"/> 25mg <input type="checkbox"/> 50mg		<input type="checkbox"/> Take 1 tablet QD <input type="checkbox"/> Take 1 tablet BID								
<input type="checkbox"/> Tivicay PD®	<input type="checkbox"/> 5mg		<input type="checkbox"/> Take _____ tablets QD <input type="checkbox"/> Disperse _____ tablets for oral suspension in _____ mL of drinking water and give QD								

PRESCRIBER INFORMATION

PRESCRIBER INFORMATION
Prescriber's Name: _____ Contact Person: _____
Telephone: _____ Fax: _____ Email: _____
Office Address: _____ City: _____ State: _____ Zip: _____
NPI # : _____ License # : _____ TAX ID # : _____ Medicaid Provider # : _____

PRESCRIBER'S SIGNATURE _____ (DATE) *IF BRAND DRUGS ARE PREFERRED, HANDWRITE "BRAND MEDICALLY NECESSARY" ABOVE

I authorize the Pharmacy noted above and its representatives to act as an agent to initiate and execute the insurance prior authorization process.

©Encore, LP All rights Reserved

IMPORTANT NOTICE: This facsimile transmission is intended to be delivered only to the named addressee and may contain material that is confidential, privileged, proprietary or exempt from disclosure under applicable law. If it is received by anyone other than the named addressee, the recipient should immediately notify the sender at the address and telephone number set forth herein and obtain instructions as to disposal of the transmitted material. In no event should such material be read or retained by anyone other than the named addressee, except by express authority of the sender to the named addressee. For information about the privacy practices of Omnicell, Inc. and its wholly owned subsidiaries or to opt-out certain uses of your personal information, please visit <https://www.omnicell.com/privacy-notice>.

© REF--HIV-E
Encore
5170 - 08-29-2023